NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
(b)On October18, 2017, David-Alexander C. Gros, M.D. resigned as the President, Chief Operating Officer and interim Chief Financial Officer of Neurocrine Biosciences, Inc. (the “Company”), effective as of October 19, 2017. Dr.Gros has agreed to remain as an employee of the Company until December31, 2017, at which time his employment with the Company will terminate and he will receive the severance benefits described in his Employment Agreement dated January4, 2017, subject to the conditions set forth therein.
“D.A. shares a love and respect for Neurocrine, where he has been a valued member of our senior team.He made important contributions during his tenure, in particular during our recent successful financing and the launch of INGREZZA.We wish him well in his future endeavors,” said Kevin C. Gorman, Chief Executive Officer of the Company.
(c)In connection with the resignation of Dr.Gros, effective October19, 2017, Dr. Gorman was appointed as the Company’s interim Chief Financial Officer. No additional compensation will be provided to Dr.Gorman in connection with his service as the Company’s interim Chief Financial Officer. A biography of Dr.Gorman is provided in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April21, 2017.
While the Company conducts its external search to identify a new executive to assume Dr.Gros’ duties, the Company’s former Chief Financial Officer, Timothy Coughlin, will support the organization until a new individual has been recruited and hired. Mr.Coughlin served as the Company’s Chief Financial Officer from September 2006 to February 2017, during a period of substantial growth for the Company and has continued to advise the Company during 2017.
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
